Smith Group Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Smith Group Asset Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-720	Closed	-$36K	–	319
2020 Q2	$36K	Sell	720 -20	-3%	-$1.03K	﹤0.01%	216
2020 Q1	$38K	Hold	740	–	–	﹤0.01%	255
2019 Q4	$46K	Hold	740	–	–	﹤0.01%	285
2019 Q3	$44K	Buy	740 +220	+42%	+$16.3K	﹤0.01%	285
2019 Q2	$44K	Hold	520	–	–	﹤0.01%	281
2019 Q1	$50K	Sell	520 -1,300	-71%	-$117K	﹤0.01%	299
2018 Q4	$129K	Sell	1,820 -200	-10%	-$15.3K	﹤0.01%	271
2018 Q3	$173K	Buy	+2,020	New	+$202K	﹤0.01%	254
2015 Q1	–	Sell	-677	Closed	-$34K	–	423
2014 Q4	$34K	Hold	677	–	–	﹤0.01%	329
2014 Q3	$27K	Hold	677	–	–	﹤0.01%	291
2014 Q2	$29K	Sell	677 -1,230	-64%	-$46.9K	﹤0.01%	297
2014 Q1	$76K	Sell	1,907 -550	-22%	-$20K	﹤0.01%	240
2013 Q4	$67K	Hold	2,457	–	–	﹤0.01%	227
2013 Q3	$56K	Buy	+2,457	New	+$47K	﹤0.01%	236

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Smith Group Asset Management's ENTA Position: Q3 2020 in Review

Smith Group Asset Management sold out of Enanta Pharmaceuticals (ENTA) in Q3 2020, closing a stake of 720 shares — an estimated $36K sold.

Smith Group Asset Management first reported a position in ENTA in Q3 2013 and held it in 14 quarters. The position peaked at $173K in Q3 2018. 172 funds tracked by Wall St. Rank hold ENTA as of Q3 2020.

Smith Group Asset Management reported no remaining Enanta Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Smith Group Asset Management sold 720 Enanta Pharmaceuticals shares in Q3 2020, an estimated $36K.
Smith Group Asset Management first reported a position in Enanta Pharmaceuticals in Q3 2013 and held it in 14 quarters.
Smith Group Asset Management's Enanta Pharmaceuticals position peaked at $173K in Q3 2018.
172 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2020.

Based on Smith Group Asset Management's 13F filing for Q3 2020, filed 4 Nov 2020.